- Trial phase
- Approved
- Time to market
- Already FDA-approved and commercially available since September 2018.
- Why 3/10
- AJOVY is already FDA-approved (since September 2018) with no pending PDUFA or pivotal readout in the next ~12 months; as a mature marketed drug, its share-price impact for TEVA comes through routine quarterly sales reports rather than a binary catalyst, scoring a 3.
With AJOVY already approved and generating steady revenue as part of Teva's innovative portfolio, watch the quarterly earnings calls for AJOVY sales trends relative to CGRP-class competitors (Emgality, Aimovig, Vyepti). The key TEVA catalyst to watch is the upcoming NDA submission for ecopipam (Tourette syndrome) in H2 2026, that's a more binary pipeline event than anything on AJOVY.
Price Chart
Executive Summary
AJOVY (fremanezumab) is Teva Pharmaceutical's injectable CGRP-inhibitor antibody for migraine prevention, first FDA-approved in September 2018 with subsequent supplemental approvals through mid-2026 covering labeling and efficacy updates. It is one of Teva's key innovative products alongside AUSTEDO and UZEDY, a portfolio that grew 41% year-over-year in Q1 2026. However, AJOVY is a mature, marketed drug with no pending binary catalyst; it competes in a crowded CGRP class against Aimovig, Emgality, Vyepti, and multiple oral CGRP antagonists. For investors, AJOVY contributes steady revenues but is not the primary catalyst for Teva shares, watch ecopipam's NDA submission and Teva's generics recovery for the bigger stock-moving events.
How It Works
Fremanezumab is a monoclonal antibody (a manufactured immune-system protein) that blocks a molecule called CGRP, which is involved in transmitting migraine pain signals. By binding to CGRP and preventing it from docking onto receptors, the drug reduces the frequency and severity of migraine attacks. It is given as a subcutaneous injection (just under the skin) either once a month or once every three months.
Trial Status
Approved for migraine prevention. The original Phase 3 HALO program (two pivotal trials in episodic and chronic migraine) met primary endpoints. Subsequent supplemental approvals for labeling updates (most recent: June 2026) and an efficacy supplement (August 2025, priority review) have been granted.
The Two-Sided Case
Upcoming Catalysts
- No near-term binary catalyst for AJOVY specifically, it is a mature marketed product.
- Watch Teva quarterly earnings for AJOVY sales trends within the innovative products segment.
- Teva's key upcoming catalyst is the ecopipam NDA submission for Tourette syndrome expected in H2 2026.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
TEVA PHARMACEUTICAL INDUSTRIES LTD 8-K TEVA ·Originating report